Liver toxicity caused by nevirapine

Area of Science:

• Pharmacology
• Hepatology
• Infectious Diseases

Background:

• Nevirapine is a key antiretroviral medication for HIV treatment.
• Hepatotoxicity is a known adverse effect of nevirapine therapy.
• Hepatitis C virus (HCV) coinfection is common in HIV patients and can exacerbate liver disease.

Purpose of the Study:

• To identify predictors of nevirapine-induced liver toxicity in HIV-infected patients.
• To assess the impact of nevirapine plasma levels and HCV infection on transaminase elevations.
• To determine specific nevirapine concentration thresholds associated with liver toxicity in HCV-coinfected individuals.

Main Methods:

• Prospective measurement of nevirapine plasma concentrations in 70 HIV-infected patients.
• Assessment of transaminase levels to identify liver toxicity.
• Statistical analysis to determine independent predictors of hepatotoxicity, including HCV status and nevirapine levels.

Main Results:

• Transaminase elevations occurred in 33 out of 70 patients.
• Higher nevirapine plasma levels were an independent predictor of liver toxicity.
• Hepatitis C virus infection was also an independent predictor of liver toxicity.
• In patients with chronic hepatitis C, nevirapine concentrations >6 microg/ml were linked to a 92% risk of liver toxicity.

Conclusions:

• Nevirapine plasma levels and HCV infection are significant risk factors for liver toxicity.
• Therapeutic drug monitoring of nevirapine is advisable, especially in HIV patients coinfected with chronic hepatitis C.
• Close monitoring may help prevent severe hepatotoxicity and guide nevirapine dosage adjustments.